Literature DB >> 709516

Circulating carcinoembryonic antigen in pancreatic carcinoma.

M H Kalser, J S Barkin, D Redlhammer, A Heal.   

Abstract

Circulating CEA levels were determined in 102 patients wtih histologically proven pancreatic carcinoma and 26 patients with chronic pancreatitis. In the group with pancreatic carcinoma eleven patients had resectable tumors, the mean CEA in the nonjaundiced patients was 10 +/- 5 ng/ml while the mean value in jaundiced patients in this group was 27 +/- 40. Thirty-four patients with nonmetastatic locally unresectable disease had a mean serum CEA of 25 +/- 52 with a range of 1 to 250 ng/ml. Twenty-one percent had values of 5 ng/ml or less. The mean value in 57 patients with metastatic disease was 97 +/- 194 with a range of 0.05 to 1000 ng/ml and 19 percent had values of 5 ng/ml or less. Survival of patients with locally unresectable or metastatic carcinoma was significantly longer in those patients who had a normal CEA at the time of diagnosis. Circulating CEA in the metastatic group was much lower in patients with nonhepatic metastases as well as in those with well differentiated adenocarcinoma histology. Twenty-three patients with chronic pancreatitis and normal serum bilirubin had a mean CEA value of 5.3 +/- 4 ng/ml with 65% of values being 5 ng/ml or less but the CEA ranged from 4.6 to 27 in three who were jaundiced.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709516     DOI: 10.1002/1097-0142(197809)42:3+<1468::aid-cncr2820420816>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Serologic markers in the diagnosis and management of pancreatic carcinoma.

Authors:  D K Podolsky
Journal:  World J Surg       Date:  1984-12       Impact factor: 3.352

2.  Monoclonal antibodies against CEA-related components discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias.

Authors:  B Bätge; K Bosslet; H H Sedlacek; H F Kern; G Klöppel
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

3.  Epithelial markers in pancreatic carcinoma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2.

Authors:  E Heyderman; S E Larkin; P J O'Donnell; A M Haines; P J Warren; A Northeast; A G Grant
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

4.  Signet ring carcinoma of the pancreas, a rare variant with very high CEA values. Immunohistologic comparison with adenocarcinoma.

Authors:  K J Tracey; M J O'Brien; L F Williams; M Klibaner; P K George; C A Saravis; N Zamcheck
Journal:  Dig Dis Sci       Date:  1984-06       Impact factor: 3.199

5.  Diagnostic value of cerebrospinal fluid level of carcinoembryonic antigen in patients with leptomeningeal carcinomatous metastasis.

Authors:  Sung Jin Kang; Kwang Soo Kim; Yoon Suk Ha; So Young Huh; Ji Hyun Lee; Jong Kuk Kim; Min Jeong Kim
Journal:  J Clin Neurol       Date:  2010-03-26       Impact factor: 3.077

6.  Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?

Authors:  A Panucci; C Fabris; G Del Favero; D Basso; F Di Mario; L Marchioro; A Piccoli; M Lise; A Burlina; R Naccarato
Journal:  J Clin Pathol       Date:  1986-01       Impact factor: 3.411

Review 7.  The detection and evaluation of human tumor metastases.

Authors:  D J Laurence; A M Neville
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

8.  Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.

Authors:  Kyong Joo Lee; Seung Woo Yi; Moon Jae Chung; Seung Woo Park; Si Young Song; Jae Bock Chung; Jeong Youp Park
Journal:  Yonsei Med J       Date:  2013-05-01       Impact factor: 2.759

9.  Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

10.  The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

Authors:  J Lundin; P J Roberts; P Kuusela; C Haglund
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.